Modality
Peptide
MOA
Anti-Tau
Target
USP1
Pathway
DDR
RettOvarian Ca
Development Pipeline
Preclinical
~May 2020
→ ~Aug 2021
Phase 1
~Nov 2021
→ ~Feb 2023
Phase 2
~May 2023
→ ~Aug 2024
Phase 3
Nov 2024
→ Oct 2025
Phase 3Current
NCT05375405
2,357 pts·Ovarian Ca
2024-11→2025-10·Recruiting
2,357 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-10-205mo agoPh3 Readout· Ovarian Ca
Trial Timeline
2025Q2Q3Q4
P3
Recruit…
Catalysts
Ph3 Readout
2025-10-20 · 5mo ago
Ovarian Ca
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05375405 | Phase 3 | Ovarian Ca | Recruiting | 2357 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| NVS-5439 | Novartis | Preclinical | BET | |
| ABB-2476 | AbbVie | Phase 1/2 | USP1 | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| REG-2172 | Regeneron | Phase 1/2 | PCSK9 | |
| BGN-3305 | BeiGene | Phase 2 | BCMA | |
| Sovarasimod | Halozyme | Phase 1/2 | WEE1 | |
| Voxamavacamten | Corcept | Approved | BET | |
| Zenonaritide | Arvinas | Phase 1/2 | BCL-2 | |
| Tezesotorasib | Enliven | Phase 2 | USP1 |